Join the LST Foundation and Adam Haberle, PhD, MBA for a session focused on early research strategies for clinical and regulatory success.
Hosted in person and broadcasted virtually via Zoom, this session will explore how life science startups can strategically plan their early research to maximize the probability of a technical and regulatory success. Discussion will include designing studies that generate decision-enabling data, preparing for regulatory engagement, and avoiding common pitfalls that slow progress from the benchtop to the bedside.
Adam Haeberle is a Senior Director in Clinical Development at Nkarta Therapeutics, a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, founded in 2015. The company develops “off-the-shelf” engineered natural killer (NK) cell therapies, utilizing NK cells’ tumor-killing properties to treat autoimmune diseases.
Prior to Nkarta, Adam was at Vertex Pharmaceuticals where he was the Program Lead Clinical Scientist for Genetic Kidney Disease to include one program in a global registrational P3 study and a second program in a P2 POC study. During his 20 years in industry Adam has worked in roles of increasing responsibility in both small and large companies to include Amgen and Baxter Bioscience. He has led early development for a small publicly traded biotech company. During his tenure he has filed 4 INDs and has been a team member for two successful NDA/BLA filings.
Adam has multiple patents, including one in the rare disease space that was acquired by Takeda in a milestone based acquisition.
Educationally, Adam has a PhD in Neuroscience with a concentration in Cell and Molecular Biology from Louisiana State University Health Sciences Center and an MBA from Pepperdine University.
The event will take place from 3:30-5 p.m. CT. Location and Zoom details can be found on the registration page.
